Wire · operational-macro
Pfizer pares back obesity pipeline, drops phase 2-stage lung disease candidate
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 November 2026 · Fusion42 review
Pfizer has terminated several mid- and early-stage drug development programs including a phase 2 pulmonary arterial hypertension candidate, two obesity drug candidates, and two KRAS inhibitors for solid tumors, citing business reasons rather than safety or efficacy concerns.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Pfizer's pause on diverse mid-stage drug candidates signals a strategic focus shift that opens space for competitors in obesity and pulmonary arterial hypertension. You can exploit gaps in late-stage obesity and lung disease treatments left behind by Pfizer's pullback.
◆ Coverage
1 source · 3 Nov 2026
◆ Related on Wire
◆ Topics